Stephen Pettit graduated from the University of Newcastle upon Tyne, having completed a PhD in tumour and transplant immunology during his basic medical training. He undertook general medical training in the West of Scotland and higher specialist training in the Mersey Deanery, including sub-specialty training at the Golden Jubilee National Hospital, Glasgow and Papworth Hospital. His areas of sub-specialist interest are advanced heart failure, device therapy, mechanical circulatory support and heart transplantation. He is an accredited Cardiac Device Specialist with the International Board of Heart Rhythm Examiners and the European Heart Rhythm Association.
Stephen Pettit was appointed a Consultant Cardiologist at Papworth in 2014. As part of a multi-disciplinary team, he looks after patients with advanced heart failure, patients that have undergone heart transplantation and those that are being bridged to transplantation with ventricular assist devices. In addition, he is involved with implantation and follow-up of patients with cardiac resynchronisation therapy devices and implantable cardioverter-defibrillators.
Advanced Heart Failure, Device Therapy, Mechanical Circulatory Support, Cardiac Transplantation
Prognostication in Advanced Heart Failure
Use of Cardiac Resynchronisation Therapy and Implantable Cardioverter-Defibrillators
MB BS (Hons), University of Newcastle upon Tyne, 2002
PhD, University of Newcastle upon Tyne, 2002
MRCP (UK), Royal College of Physicians of London, 2005
Diploma in Mountain Medicine, UIAA/IKAR/ISMM, 2007
Certified Cardiac Device Specialist, International Board of Heart Rhythm Examiners, 2011
Accredited RCP Educator, Royal College of Physicians of London, 2012
Certified Cardiac Device Specialist, European Heart Rhythm Association, 2013
Fellow of the Royal College of Physicians of London
Treasurer and Board Member, British Society of Heart Failure
Member of the British Cardiovascular Society
Senior clinical tutor, University of Cambridge
Cesini S, Bhagra S, Pettit S. Low pulmonary artery pulsatility index is associated with adverse outcomes in ambulatory patients with advanced heart failure. J Cardiac Fail 2020; 26:352-359.
Ton V, Xie R, Hernandez-Montfort J, Meyns B, Nakatani T, Yanase M, Shaw S, Pettit S, Netuka I, Kirklin J, Goldstein D, Cowger J. Short and long-term adverse events in patients on temporary circulatory support before durable ventricular assist device: An iMACS registry analysis. J Heart Lung Transplant 2020; 39:342-352.
Hernandez-Montfort J, Xie R, Ton V, Meyns B, Nakatani T, Yanase M, Pettit S, Shaw S, Netuka I, Kirklin J, Goldstein D, Cowger J. Longitudinal impact of temporary mechanical circulatory support on durable ventricular assist device outcomes: An IMACS registry propensity matched analysis.
J Heart Lung Transplant 2020; 39:145-156. PMID 31866174
Fung K, Cheshire C, Cooper JA, Catarino P, Bhagra S, Pettit S, Petersen SE. Validation of cardiovascular magnetic resonance-derived equations for predicted left ventricular mass using the UK biobank imaging cohort. Circulation Heart Fail 2019; 12:e006362.
Goldstein DJ, Meyns B, Xie R, Cowger J, Pettit S, Nakatani T, Netuka I, Shaw S, Yanase M, Kirklin JK. Third Annual Report From the ISHLT Mechanically Assisted Circulatory Support Registry: A comparison of centrifugal and axial continuous-flow left ventricular assist devices. J Heart Lung Transplant 2019; 38: 352-363.
Barra S, Duehmke R, Providencia R, Narayanan K, Reitan C, Roubicek T, Polasek R, Chow A, Pettit S, Defaye P, Fauchier L, Piot O, Deharo J-C, Sadoul N, Klug D, Garcia R, Virdee M, Agarwal S, Borgquist R, Marijon E, Boveda S. Very long-term survival and late sudden cardiac death in cardiac resynchronisation therapy patients. Eur Heart J 2019; 40: 2121-2127.
Fitzsimons S, Evans J, Parameshwar J, Pettit SJ. Utility of Troponin assays for exclusion of acute cellular rejection after heart transplantation: A systematic review. J Heart Lung Transplant 2018; 37: 631-638.
Evans JDW, Dobbin S, Pettit SJ, Di Angelantonio E, Willeit P. High Sensitivity Cardiac Troponin and New Onset Heart Failure: A Systematic Review and Meta-Analysis of 67,063 individuals with 4,165 incident heart failure events. JACC Heart Fail 2018; 6: 187-197.
Pettit SJ, Orzalkiewicz M, Nawaz MA, Lewis C, Parameshwar JK, Tsui S. Retained pacemaker and implantable cardioverter-defibrillator components after heart transplantation are common and may lead to adverse events.
Europace 2018; 20: 1312-1317.
Messer S, Page A, Axell R, Berman M, Hernández-Sánchez J, Colah S, Parizkova B, Valchanov K, Dunning J, Pavlushkov E, Balasubramanian SK, Parameshwar J, Abu Omar Y, Goddard M, Pettit S, Lewis C, Kydd A, Jenkins D, Watson CJ, Sudarshan C, Catarino P, Findlay M, Ali A, Tsui S, LargeSR. Outcome Following Heart Transplantation from Donation After Circulatory Determined Death (DCD) Donors.
J Heart Lung Transplant 2017; 36: 1311-1318.
Evans JDW, Kaptoge S, Caleyachetty R, Di Angelantonio E, Lewis C, Parameshwar KJ, Pettit SJ. Socioeconomic deprivation and survival after heart transplantation in England: an analysis of the United Kingdom Transplant Registry. Circulation Cardiovasc Qual Outcomes 2016; 9:695-703.
Evans JDW, Pettit SJ, Goddard M, Lewis C, Parameshwar KJ. Alemtuzumab as a novel treatment for refractory giant cell myocarditis after heart transplantation. J Heart Lung Transplant 2016;35:256-258.
Pettit SJ, Shapiro LM, Lewis C, Parameshwar JK, Tsui SSL. Percutaneous withdrawal of HeartWare HVAD left ventricular assist device support. J Heart Lung Transplant 2015;34:990-992.
Pettit SJ, Jhund PS, Hawkins NM, Gardner RS, Haj-Yahia S, McMurray JJV, Petrie MC. How small is too small? A systematic review of centre volume and outcome after cardiac transplantation. Circulation Cardiovasc Qual Outcomes 2012;5:783-790.
